IMG_8184

phase I/II trial, it induced neutralizing antibodies against SARS-CoV-2 in all 1,077 participants after a second vaccine dose, while its safety profile was acceptable as well’. The NIAID and Moderna co-manufactured mRNA- 1273, a lipid nanoparticle-formulated mRNA vaccine candidate that encodes the stabilized prefusion SARS-CoV-2 S protein. Its immunogenicity has been confirmed by a phase I trial in which robust neutralizing antibody responses were induced in a dose-dependent manner and increased after a second dose'™. Regarding inactivated vaccines, a successful phase I/II trial involv- ing 320 participants has been reported in China. The whole-virus COVID-19 vaccine had a low rate of adverse reactions and effectively induced neutralizing antibody production’. The verified safety and immunogenicity support advancement of these vaccine candidates to phase III clinical trials, which will evaluate their efficacy in protecting healthy populations from SARS-CoV-2 infection. Future perspectives COVID-19 is the third highly pathogenic human coro- navirus disease to date. Although less deadly than SARS and MERS, the rapid spreading of this highly conta- gious disease has posed the severest threat to global health in this century. The SARS-CoV-2 outbreak has lasted for more than half a year now, and it is likely that